• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    5 Value Stocks In The Healthcare Sector

    12/5/22 9:43:35 AM ET
    $APVO
    $CO
    $FLGT
    $JSPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care
    Health Care
    Get the next $APVO alert in real time by email

    The Meaning Behind Value Stocks

    A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

    Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:

    1. ProPhase Labs (NASDAQ:PRPH) - P/E: 5.74
    2. Aptevo Therapeutics (NASDAQ:APVO) - P/E: 2.84
    3. Global Cord Blood (NYSE:CO) - P/E: 5.11
    4. Jasper Therapeutics (NASDAQ:JSPR) - P/E: 0.16
    5. Fulgent Genetics (NASDAQ:FLGT) - P/E: 4.15

    ProPhase Labs saw a decrease in earnings per share from 0.4 in Q2 to $0.06 now. Most recently, Aptevo Therapeutics reported earnings per share at $-1.5, whereas in Q2 earnings per share sat at $-1.82. Global Cord Blood saw a decrease in earnings per share from 0.17 in Q3 to $0.14 now. Jasper Therapeutics saw a decrease in earnings per share from -0.29 in Q2 to $-0.32 now. Fulgent Genetics's earnings per share for Q3 sits at $0.32, whereas in Q2, they were at 0.78.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $APVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APVO
    $CO
    $FLGT
    $JSPR

    CompanyDatePrice TargetRatingAnalyst
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    Fulgent Genetics Inc.
    $FLGT
    8/5/2025$30.00Neutral → Buy
    UBS
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$4.00Outperform → Market Perform
    BMO Capital Markets
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$5.00Outperform → Sector Perform
    RBC Capital Mkts
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Overweight → Neutral
    Cantor Fitzgerald
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Outperform → Mkt Perform
    William Blair
    Jasper Therapeutics Inc.
    $JSPR
    2/13/2025$38.00Buy
    UBS
    Jasper Therapeutics Inc.
    $JSPR
    12/6/2024$63.00Outperform
    BMO Capital Markets
    More analyst ratings

    $APVO
    $CO
    $FLGT
    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About F

    2/12/26 7:30:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative

    Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart™, its clinically validated esophageal cancer risk stratification test, and is advancing its Crown Medical Collections initiative, with each initiative independently offering the potential to drive significant liquidity and materially strengthen the Company's balance sheet. BE-Smart™ Sale and Strategic Partne

    2/3/26 7:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on February 3rd

    UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company") is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Labs Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase's dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent milestones, including full U.S. patent approval and clinical validation of its BE-Smart™ Esophageal Cancer Test, a groundbreaking diagnostic designed for early cancer detection in a $7–14 billion

    2/2/26 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $CO
    $FLGT
    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wiggans Thomas G bought $99,630 worth of Voting Common Stock (41,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucas Svetlana bought $48,600 worth of Voting Common Stock (20,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:38 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $CO
    $FLGT
    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Mahal Jeetinder Singh

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    2/10/26 4:00:23 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Gao Hanlin covered exercise/tax liability with 1,331 shares, decreasing direct ownership by 0.14% to 951,559 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    1/28/26 5:02:27 PM ET
    $FLGT
    Medical Specialities
    Health Care

    President and COO Xie Jian covered exercise/tax liability with 4,711 shares, decreasing direct ownership by 1% to 332,038 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    1/28/26 5:02:08 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $APVO
    $CO
    $FLGT
    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fulgent Genetics upgraded by UBS with a new price target

    UBS upgraded Fulgent Genetics from Neutral to Buy and set a new price target of $30.00

    8/5/25 7:03:39 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Jasper Therapeutics downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Jasper Therapeutics from Outperform to Market Perform and set a new price target of $4.00

    7/8/25 8:30:26 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $CO
    $FLGT
    $JSPR
    SEC Filings

    View All

    ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    2/13/26 5:15:51 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    2/13/26 5:15:50 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.

    SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/12/26 10:33:02 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $CO
    $FLGT
    $JSPR
    Leadership Updates

    Live Leadership Updates

    View All

    Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

    Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics ("Bako"), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately $55.5 m

    12/22/25 4:10:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    $APVO
    $CO
    $FLGT
    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

    SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/14/24 3:45:38 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 3:32:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $CO
    $FLGT
    $JSPR
    Financials

    Live finance-specific insights

    View All

    Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About F

    2/12/26 7:30:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care